KANJINTI subst sèche 150 mg flac
7680672050010
CH-67205
L01FD01
07.16.1.
Reimbursement limitations:
KANJINTI.01
KANJINTI en association avec le pertuzumab (PERJETA) comme traitement adjuvant du cancer du sein
Les …
1 / 3
google
Details
- Product number
- 6720501
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- Praeparatio cryodesiccata: trastuzumabum 150 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, pro vitro.
Articles (1)
Kanjinti 150 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
PRC
|
150.0 MG | Substance | Wirkstoff (Principe actif) |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 513.25
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/02/2020
Authorization holder
Amgen Switzerland AG
6343 Risch
Authorization information
- Swissmedic authorization number
- 67205
- Drug name
- Kanjinti, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- PULPI
- ATC Code
- L01FD01
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 11/11/2019
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- KANJINTI subst sèche 150 mg flac
- Description (DE)
- KANJINTI Trockensub 150 mg Durchstf
- Market launch
- 11/11/2019
- Narcotic (BTM)
- No